Arsenic Trioxide
NPMc+ AML
The University of Hong KongSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
14 Active assets in the NPMc+ AML cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytosin-Arabinosid Shen yang | Phase 3 | B |
Azacitidine Shen yang | Phase 2 | B |
Venetoclax Kura Oncology, Inc. | Phase 2 | B |
Daunorubicin Shen yang | Phase 2 | B |
BN104 Institut de Recherches Internationales Servier (I.R.I.S.) | Phase 1/2 | CC |
View all 14 →
Same molecule, other indications
Arsenic Trioxide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →